ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF

Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.


Symbol Grade Price % Change Allocation
PACB D -13.93 6.85
TDOC C -13.57 5.94
CRSP F -5.16 5.77
TWST F -5.63 5.72
CDNA D 2.25 3.87
IOVA F -7.03 3.59
EXAS D -3.88 3.58
FATE D -9.84 3.47
NVTA F -5.63 3.42
PSNL F -10.22 3.26
REGN F -0.94 2.88
NVS F -0.81 2.65
PSTG C -7.75 2.57
VRTX F -1.56 2.54
ARCT F -7.68 2.26
GOOGL C -2.93 2.17
CLLS F -8.90 2.16
TAK F -2.73 2.06
INCY F -3.06 2.04
CSTL D -9.99 1.83
IONS F -5.37 1.79
BLI F -8.52 1.72
EDIT F -10.20 1.68
NTLA D -10.26 1.57
SDGR B -5.58 1.45
VCYT D -6.65 1.39
ACCD F -6.21 1.36
BEAM D -9.53 1.22
ADPT D -5.87 1.20
TMO F -1.10 1.16
MCRB F -5.40 1.15
CDXS D -7.60 1.14
VEEV C -3.11 1.09
AQB F -8.53 1.00
TXG C -4.29 0.99
PHR D -4.29 0.94
GH C -8.23 0.92
NSTG C -6.94 0.90
CERS D -4.64 0.75
SRPT F 1.44 0.55
SYRS F -5.97 0.45
LGVW.U F 0.00 0.39
SURF F -7.48 0.31
RPTX F -1.32 0.29
ONVO D -7.32 0.06

Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

Date Stock Title
Feb 25 EDIT Editas Medicine downgraded to underweight at JP Morgan on lack of catalysts
Feb 25 CDXS Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results
Feb 25 REGN ‘Covid-19 has been the perfect storm for adversaries’ in cybersecurity industry: CrowdStrike
Feb 25 CERS Cerus Corp. to Host Earnings Call
Feb 25 REGN Doctor: New COVID-19 strains come from ‘robust transmission of the virus’
Feb 25 EDIT Editas Medicine's (EDIT) CEO Jim Mullen on Q4 2020 Results - Earnings Call Transcript
Feb 25 EDIT Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
Feb 25 GOOGL This little-known Google feature might have saved a man’s life - and here’s how to get it
Feb 25 GOOGL House members assail Big Tech (again), consider changes to antitrust law
Feb 25 GH Why Guardant Health Stock Is Sinking Today
Feb 25 TDOC Stocks Today Fall But Moderna Surges Off Key Level; This Pot Stock Tanks 14%, Teladoc Drops
Feb 25 REGN Positive news on COVID vaccines weighs against concerns over new variants
Feb 25 REGN Regeneron to share new data about COVID-19 antibody cocktail in March
Feb 25 PSTG Pure Storage price targets lifted on broad-based demand strength
Feb 25 TDOC Teladoc Stock Falls on Downbeat Forecast for Membership
Feb 25 VEEV HealthTech Trends 2021: CEO’s of Teladoc, Reliq Health, Relay Medical and Veeva Systems, Driving Revenue Growth with Innovation and New Markets Expansions
Feb 25 TDOC HealthTech Trends 2021: CEO’s of Teladoc, Reliq Health, Relay Medical and Veeva Systems, Driving Revenue Growth with Innovation and New Markets Expansions
Feb 25 GOOGL #SocialStocks: Snap Shares Advance Following First Investor Day
Feb 25 GOOGL ByteDance Promotes News Unit CEO As Global TikTok R&D Head: Reuters
Feb 25 GOOGL Twitter Aims to Double Revenue in 3 Years; Shares Surge
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Exchange Traded Fund ETF Biotechnology Stem Cells Genomics Bioinformatics
Back to the Main ARKG Page...